

Journal Pre-proof

Impact of Multidisciplinary Team Meetings on Decision Making in Vascular Surgery: A Prospective Observational Study

Giorgio Prouse, Alessandro Robaldo, Jos C. van den Berg, Ludovica Ettore, Francesco Mongelli, Luca Giovannacci



PII: S1078-5884(23)00279-4

DOI: <https://doi.org/10.1016/j.ejvs.2023.03.037>

Reference: YEJVS 8734

To appear in: *European Journal of Vascular & Endovascular Surgery*

Received Date: 30 September 2022

Revised Date: 20 February 2023

Accepted Date: 21 March 2023

Please cite this article as: Prouse G, Robaldo A, van den Berg JC, Ettore L, Mongelli F, Giovannacci L, Impact of Multidisciplinary Team Meetings on Decision Making in Vascular Surgery: A Prospective Observational Study, *European Journal of Vascular & Endovascular Surgery* (2023), doi: <https://doi.org/10.1016/j.ejvs.2023.03.037>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier B.V. on behalf of European Society for Vascular Surgery.

1 **Impact of Multidisciplinary Team Meetings on Decision Making in Vascular Surgery: A**
2 **Prospective Observational Study**

3 **Giorgio Prouse^{a,*‡}, Alessandro Robaldo^{a,‡}, Jos C. van den Berg^{b,c}, Ludovica Ettorre^a,**
4 **Francesco Mongelli^{d,e}, and Luca Giovannacci^a**

5 ^aService of Vascular Surgery, Ospedale Regionale di Lugano, Centro Vascolare Ticino, EOC,
6 Lugano, Switzerland

7 ^bService of Interventional Radiology, Ospedale Regionale di Lugano, Centro Vascolare Ticino,
8 EOC, Lugano, Switzerland

9 ^cInselhospital Bern, Universitätsinstitut für Diagnostische, Interventionelle und Pädiatrische
10 Radiologie, Bern, Switzerland

11 ^dDepartment of Surgery, Ospedale Regionale di Bellinzona e Valli, EOC, Bellinzona, Switzerland

12 ^eFaculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland

13 [‡]These authors contributed equally to the study.

14 ^{*} Corresponding author. Ospedale Regionale di Lugano, Via Tesserete 46, 6900 Lugano,
15 Switzerland.

16 giorgio.prouse@eoc.ch (Giorgio Prouse).

17 **WHAT THIS PAPER ADDS**

18 Multidisciplinary team meetings (MDTs) are strongly recommended in several areas of vascular
19 disease in most guidelines (class I), yet available evidence is lacking (level C). In this study, the
20 impact that multidisciplinary discussion had on the treatment of vascular patients was prospectively
21 evaluated. The results showed that the MDT frequently led to significant changes in the treatment
22 decision compared with the treatment recommendation from a single specialist. Although further
23 research will be required to determine the concordance of treatment recommendations between
24 multidisciplinary teams and clinical decision algorithms, this study supports the guideline
25 recommendation to include structured multidisciplinary decision making for vascular patients.

26 **Objective:** This cohort study aimed to prospectively determine the impact of multidisciplinary team
27 meetings (MDTs) on treatment plans in vascular patients.

28 **Methods:** The weekly MDT at the institution consists of a structured discussion of vascular cases in
29 the presence of at least one representative of each specialty from vascular surgery, angiology, and
30 interventional radiology. Participants were asked to examine the cases entered on the digital MDT
31 platform and to fill in forms with a detailed open text treatment recommendation for each patient.
32 Individual recommendations were compared with the final MDT decision, which was based on a
33 shared decision upon discussion of clinical and radiological data. The primary endpoint was the
34 agreement rate. The rate of decision implementation was determined to verify the adherence to MDT
35 recommendations.

36 **Results:** Four hundred consecutive case discussions in 367 patients between November 2019 and
37 March 2021 were included, excluding patients needing urgent treatment, yielding MDT discussion in
38 88.5% of carotid artery cases, 83% of aorto-iliac cases, and 51.7% of peripheral arterial cases, which
39 included 56.9% of the chronic limb threatening ischaemia cases. The overall average agreement rate
40 was $71\% \pm 41\%$. Analysis according to the specialty of the attending physician showed agreement
41 rates of $82\% \pm 30\%$ for senior vascular surgeons, $62\% \pm 44\%$ for junior vascular surgeons, $71\% \pm$
42 43% for interventional radiologists, $58\% \pm 50\%$ for angiologists ($p < .001$), and $75\% \pm 38\%$
43 considering only senior practitioners. The inter-rater agreement, resulted in kappa coefficients of 0.60
44 – 0.68 for senior vascular surgeons, 0.29 – 0.31 for junior vascular surgeons, 0.39 – 0.52 for
45 interventional radiologists, and 0.25 for angiologists. The MDT treatment decision was implemented
46 in 353 (96.2%) cases.

47 **Conclusion:** The impact of MDT discussion on treatment recommendations and the adherence to
48 MDT recommendations were significant and in line with results reported from other specialties.

49 **Keywords:** Intervention, Multidisciplinary, Vascular

50 **<H1>INTRODUCTION**

51 Multidisciplinary team meetings (MDTs) were originally introduced in the care of patients with
52 cancer to address the growing complexity of decision making due to a significant increase of available
53 treatment options.^{1,2}

54 The clinical effectiveness of MDTs has subsequently been demonstrated in other areas of
55 healthcare such as congestive heart failure,³ chronic pulmonary disease,⁴ and diabetic foot care.⁵
56 Relevant guidelines and some national societies strongly recommend (class I) MDTs in vascular
57 surgery.⁶⁻¹¹ Following these recommendations, the constitution and use of vascular MDTs are
58 spreading in several countries worldwide. However, evidence on the effectiveness of MDTs in terms
59 of clinical outcome is still limited (evidence level C). Given the time and resources that are required
60 for a soundly constituted MDT, efforts have been made to produce more robust evidence of their
61 effectiveness in selected areas of vascular surgery.¹²⁻¹⁴

62 Retrospectively comparing clinical outcomes with results preceding the introduction of MDTs
63 would be biased by the evolution of devices and techniques. The retrospective quality assessment of
64 MDTs is mostly based on the determination of the rate of adherence to MDT decisions, defined as
65 the rate of decision implementation, which is a good indicator of MDT structural quality but does not
66 necessarily warrant better clinical outcomes. In this study, the MDT was hypothesised to lead to
67 significantly more weighed decisions in clinical practice compared with single physician based
68 decisions. Given the difficulties in providing evidence for the usefulness of MDTs, this study aimed
69 to assess the impact of a multidisciplinary discussion on the treatment plan proposed by individual
70 physicians.

71 <H1>MATERIALS AND METHODS

72 <H2>*Study design and patient selection*

73 This prospective cohort study was carried out in the Vascular Unit of the Ente Ospedaliero Cantonale,
74 Ticino, Switzerland, which consists of a Vascular Surgery Division, Service of Angiology, and
75 Service of Interventional Radiology, serving four hospitals in southern Switzerland. The study

76 protocol was evaluated by the local ethics committee, who waived informed consent in accordance
77 with Swiss legislation. The study protocol was not published or registered *a priori*.
78 At the institution a formally structured MDT was established in 2011, with weekly discussion of
79 vascular cases. The regulatory protocol requires the presence of at least one vascular surgeon, one
80 interventional radiologist, and one angiologist as core participants at each session. Additionally, the
81 discussion of supra-aortic vessel cases, and of thoracic aortic and of vascular access cases requires
82 the presence of at least one neurologist and one neuroradiologist, one cardiac surgeon, and one
83 nephrologist respectively. To optimise resources, revascularised patients with diabetes are discussed
84 in a separate diabetic foot MDT in the presence of a vascular surgeon, a foot surgeon, a
85 diabetologist, a specialised nurse, and an orthotic technician. Physicians with vascular activity from
86 all four hospitals are required to present all vascular cases for discussion and to actively participate
87 at the MDT, excluding only urgent cases requiring intervention sooner than the upcoming MDT. All
88 cases to be discussed have to be entered on a digital platform accessible to all MDT participants no
89 later than 3 hours before the multidisciplinary team session. Besides all digitally available clinical
90 data and imaging, the primary clinician was required to register all relevant information, including
91 the patient's personal preferences, compliance, general condition, quality of life and living
92 conditions, and all information deemed useful to meet a treatment decision. For this study, only core
93 MDT participants (three senior vascular surgeons, two junior vascular surgeons, two interventional
94 radiologists, and two angiologists) were surveyed. Additional specialists who participated in the
95 MDT discussion of specific cases did not participate in the study because of their limited
96 involvement. Participating physicians were required to provide a treatment recommendation in open
97 text format in a column on the patient presentation chart. This solution was preferable to a multiple
98 choice system, which would have generated a bias based on the determination of the available
99 treatment options to choose from. Specification of treatment details was encouraged, such as type of
100 conduit, treatment timing, type of endovascular device to be used, and all major specifications
101 regarding the procedure. If the physician was unable to propose a treatment, two additional options

102 were available, namely justified abstention (e.g., need for further investigation or clinical
103 information) and unjustified abstention. The open text recommendations were returned to the
104 principal investigator before the beginning of the MDT session. The MDT final decisions, which
105 were electronically recorded at the end of the discussion, were compared with the written single
106 physician recommendations by two independent reviewers, who had not participated in the MDT
107 session. The following criteria were applied to determine the agreement: (1) inherently different
108 procedures and different timing of procedures were considered as non-agreement; (2) similar
109 procedures with no evidence supporting one choice over the other were considered in agreement;
110 and (3) Similar procedures with evidence supporting one choice over the other were considered
111 non-agreement

112 Justified abstentions were considered in agreement only if the MDT decision also
113 recommended further investigation or integration of missing information, whereas unjustified
114 abstention was always categorised as non-agreement. The principal investigator subsequently
115 compared the evaluations of the reviewing physicians and presented all discrepancies for discussion
116 and resolution at the next MDT. All patients with vascular disease, who were discussed in the
117 multidisciplinary vascular board from November 2019 to March 2021, were prospectively included.
118 Patients requiring urgent treatment sooner than the upcoming MDT session were excluded. All cases
119 that were not entered for multidisciplinary discussion were also excluded. MDT sessions without the
120 required core participants were cancelled and the cases were rescheduled for the following session.
121 If the additionally required specialists for carotid, thoracic aortic, and vascular access cases were not
122 present, the related case was rescheduled for discussion at the next MDT. Junior and senior
123 practitioners were separated in the secondary endpoint analysis with a threshold of five years of post-
124 specialty training.¹⁵ The aim of this subanalysis was to assess the impact that MDTs may have on the
125 training of junior specialists. Participating physicians were informed about the study and were
126 provided with the study protocol.

127 <H2>*Data collection and endpoints*

128 For every patient, data were anonymised with limited access. Data included the date of board
129 discussion; vascular segment or pathology (supra-aortic, thoracic aorta, aorto-iliac segment, endoleak
130 related, peripheral arterial, arterio-venous fistulas, visceral arteries, central venous, arterio-venous
131 malformations); proposed treatment of senior and junior vascular surgeons, interventional
132 radiologists, and angiologists; decision of the primary clinician, and final board decision. All patients
133 were followed up until completion of recommended treatment. When conservative treatment was
134 recommended, it was considered implemented if it was maintained until new clinical events occurred.

135 The primary endpoint was the agreement rate with the final MDT decision, which was
136 determined by two independent reviewers. The secondary endpoints were the agreement rate in
137 subgroup analysis according to specialty, experience, vascular district, or pathology involved and
138 between the primary physician and other attending physicians who had no previous clinical encounter
139 with the patient. The variability of agreement over time in junior vascular surgeons was also analysed.
140 Junior practitioners from other specialties do not routinely participate in MDT sessions and could not
141 be included in the study. The rate of decision implementation was determined, and the reasons for
142 non-implementation were followed up. The inter-rater agreement¹⁶ was defined as the degree of
143 accordance among independent participants to the vascular board who assessed the same patients.

144 <H2>*Statistical analysis*

145 Descriptive statistics were presented as absolute frequencies for categorical variables with mean and
146 standard deviation or median with interquartile ranges (IQRs) and 95% confidence interval (95% CI)
147 for continuous variables. The chi-squared test was used to compare dichotomous values, whereas
148 analysis of variance was used to compare continuous variables.

149 Cohen's kappa coefficient was used to measure the inter-rater agreement, also providing the
150 95% CI. The sample size of 187 cases was estimated assuming a Cohen's kappa of 0.44, a minimum
151 acceptable kappa (k_0) of .2, a two-tailed significance level of .05, and a power of .8.¹⁷⁻¹⁹ Statistical
152 significance was considered at $p < .05$ and the Bonferroni adjustment was used to correct the p value

153 threshold in case of multiple comparisons for the primary outcome. Statistical analyses were
154 performed using MedCalc Statistical Software version 20.013 (MedCalc Software Ltd., Ostend,
155 Belgium; <https://www.medcalc.org>; 2021).

156 <H1>RESULTS

157 Four hundred case discussions in 367 patients took place at the multidisciplinary vascular board
158 between November 2019 and March 2021. Thirty-two (8.7%) cases were discussed in multiple
159 sessions, of which 31 were discussed twice and one was discussed three times, the latter because of
160 intercurrent clinical events and change in the patient's preference. Fourteen (3.8%) cases were re-
161 presented by the treating physician to propose a change in treatment recommendation or a re-
162 discussion after further findings: in two cases the original treatment recommendation was confirmed.
163 The MDT was cancelled twice for unattendance of the required participants and all cases were re-
164 scheduled for the following session. Fifty-four cases (13.5%) pertained to supra-aortic vessels, 16
165 (4.0%) to thoracic aorta, 131 (32.7%) to aorto-iliac segment pathologies, 33 (8.3%) to endoleaks after
166 endovascular repair of aortic lesions, 98 (24.5%) to peripheral arterial disease, 21 (5.2%) to dialysis
167 access, 29 (7.2%) to visceral arteries, 12 (3.0%) to central venous disease, and six (1.5%) to arterio-
168 venous malformations. Of all non-urgent cases, 99.2% were discussed and included in the study,
169 excluding amputations and peripheral venous cases. Three patients with intermittent claudication
170 were directly referred to the interventional radiologist by an external angiologist without MDT
171 discussion. During the study time, 141 urgent cases were treated without prior MDT discussion,
172 yielding a multidisciplinary discussion in 88.5% of carotid artery cases, and 83% of aorto-iliac cases,
173 51.7% of peripheral arterial cases (56.9% of chronic limb threatening ischaemia cases, 95.1% of
174 intermittent claudication cases, 4.7% of acute and acute on chronic ischaemia cases). The study period
175 overlapped the first two Covid-19 waves in Switzerland. During the pandemic there was a decrease
176 in consultations, in non-urgent referrals and in elective activity. This increased the proportion of
177 urgent treatments (37.2% of all cases), most of which (74.6%) could not be discussed at the MDT.

178 Although the minimum requirement for MDT validity was the presence of one senior vascular
179 surgeon, one interventional radiologist, and one angiologist, in 47% of discussed cases a second
180 radiologist was present, in 98% two or more senior vascular surgeons were present, and in 93% at
181 least one junior vascular surgeon was present and in 34% a second angiologist was present. Three
182 hundred and sixty-eight (92%) cases had at least one clinical assessment with the primary clinician
183 prior to MDT presentation. On average, the agreement rate with final board decision was $71\% \pm 41\%$
184 considering all participants. Subgroup analyses according to specialty and years of experience (Fig.
185 1) showed agreement in $82\% \pm 30\%$ for senior vascular surgeons, $62\% \pm 45\%$ for junior vascular
186 surgeons, $71\% \pm 43\%$ for interventional radiologists, $58\% \pm 50\%$ for angiologists ($p < .001$ between
187 all groups except between angiologists and junior surgeons) and $75\% \pm 38\%$ considering only senior
188 practitioners regardless of specialty. No significant difference ($p = .18$) was observed when
189 comparing the agreement rates of the primary clinician ($69\% \pm 48\%$) with those of other attending
190 physicians ($75\% \pm 41\%$). According to the Bonferroni adjustment for multiple comparisons, a p value
191 threshold of .005 was considered statistically significant. Therefore, a significant difference in
192 agreement rate could be still detected between all specialties except for junior surgeons vs.
193 angiologists who scored similarly.

194 A detailed subgroup analysis according to the vascular segment and pathology is shown in
195 Table 1. Regarding the inter-rater agreement, the kappa coefficient was 0.59 (95% CI 0.50 – 0.68),
196 0.66 (95% CI 0.58 – 0.75), and 0.67 (95% CI 0.59 – 0.76) for senior vascular surgeons, 0.24 (95%
197 CI 0.12 – 0.37) and 0.25 (95% CI 0.13 – 0.38) for junior vascular surgeons, 0.35 (95% CI 0.22 –
198 0.48) to 0.49 (95% CI 0.36 – 0.61) for interventional radiologists, and 0.13 (95% CI 0 – 0.34) for the
199 angiologists. The MDT decision was implemented in 353 (96.2%) cases. Of the 12 non-implemented
200 cases, four patients refused treatment; two patients were treated elsewhere; two patients were found
201 to have concomitant disease deemed prohibitive at pre-operative work up; three patients had severe
202 complications due to treatment of a concomitant disease; and one patient died from myocardial
203 infarction before treatment. No patients were lost to treatment implementation follow up.

204 To assess the impact of MDTs on the training of young vascular surgeons, the variability of
205 agreement over time for junior vascular surgeons was analysed by dividing the study period in three
206 equal segments and comparing their performance. The agreement rate was $59.6\% \pm 46.1\%$ in the first
207 period and $65.1\% \pm 44.3\%$ in the last. However, this difference did not reach statistical significance
208 ($p = .33$).

209 <H1>DISCUSSION

210 Most recent guidelines strongly recommend a structured multidisciplinary approach for the treatment
211 of vascular patients. However, strong evidence supporting the effectiveness of MDTs in terms of
212 improved clinical outcome is difficult to obtain even in cancer care^{20,21} and is lacking in the treatment
213 of many areas of vascular disease. Moreover, the organisation and implementation of MDTs remain
214 time and resource consuming. The present study found that individual treatment recommendations
215 were in agreement with MDT decisions in 71% of cases considering all participants, regardless of
216 specialty and years of post-specialisation experience. Even when including only practitioners with at
217 least five years of post-specialty experience, the agreement rate did not exceed 75%. Senior vascular
218 surgeons and interventional radiologists displayed the highest agreement rates (82% and 71%) due to
219 their detailed knowledge of available treatment options. Senior vascular surgeons displayed the
220 highest agreement rate in most areas. This may indicate an excessive influence in the discussion and
221 decision process, which represents a potential bias. When observing the general trend in agreement
222 rates, the performance of interventional radiologists significantly decreased in the discussion of supra-
223 aortic vessel disease. The reason for this was the difference in experience between the two
224 interventional radiologists who participated in the study, where one had limited experience in
225 treatment in this area. In this study, the agreement rate of angiologists was significantly lower in most
226 areas. This can be explained by the fact that strict parameters in evaluating the agreement of two
227 proposed treatments were applied. Different technical aspects, such as type of approach and type of
228 materials used, for which there is available evidence, were considered not equivalent in the
229 evaluation by the two reviewers. At the institution angiologists do not take part in interventional

230 procedures, which may limit their knowledge of some technical aspects of open and endovascular
231 procedures. Interestingly, the shared decision did not match any of the proposed treatments in five
232 cases, indicating that multidisciplinary discussion generated an option that had not been considered
233 during individual evaluation. Even though it is a small percentage, it highlights the synergistic effect
234 of structured case discussions. The wide standard deviation (SD) in the results indicates that there
235 was a relevant variability in the number of specialists who agreed with the MDT decision. The overall
236 results are comparable with data published for a thoracic multidisciplinary tumour board,²² where
237 MDT recommendations differed from the initial treatment plan in 26% of patients with oesophageal
238 cancer and 40% of patients with lung cancer.

239 The rate of decision implementation has often been used as a MDT structural quality indicator.
240 This study showed an implementation rate of 96.2%. This is in the upper end of reported rates that
241 ranged between 69% and 97%.^{13,22–26} Strategies to yield a high rate of implementation in cancer
242 MDTs have been thoroughly studied and described in some relevant reviews.^{27,28}

243 The common impression among participating physicians in this study was that the extra time
244 spent to carefully evaluate the cases before the MDT was greatly outweighed by an increase in quality
245 and time efficiency of the MDT discussion itself. Junior participants also seemed to profit more from
246 the multidisciplinary discussion by being required to provide a treatment plan prior to discussion.
247 However, the progression of their agreement rate over the study period did not reach statistical
248 significance.

249 <H2>*Study limitations*

250 This study has limitations. Primarily, the treatment plans proposed by the MDT attending physicians
251 other than the primary clinician, who has had at least one clinical encounter with the patient in most
252 cases, are mostly based on clinical data and imaging. A personal encounter together with a direct
253 physical examination of the patient may influence the choice of a recommended treatment. To
254 mitigate this effect, all primary clinicians were asked to provide essential information about quality
255 of life, level of fitness, and personal preference on the electronic platform prior to MDT discussion.

256 These patient centred assessments carry by default some degree of personal interpretation by the
257 primary clinician, who may have influenced the individual decision of other physicians. This strategy
258 may have reduced the decisional difference between the primary clinician and all other attending
259 physicians, making it non-significant ($69\% \pm 48\%$ and $75\% \pm 41\%$, respectively). It is also important
260 to acknowledge that the results reported are relevant to the setting of the MDT. The development of
261 a treatment strategy is known to be affected by the expertise and by several infrastructural parameters.
262 There is also a lack of consensus regarding the constitution and ruling of MDTs. For these reasons it
263 is difficult to determine the exact applicability to other centres across Europe and globally.

264 The activity of angiologists and their degree of involvement in interventional procedures may
265 also vary greatly between different centres and countries. As mentioned in Materials and Methods,
266 participating physicians were informed about the study and its aims, making results potentially
267 influenced by observer bias. A further limitation is intrinsic to the structure of the MDT that does not
268 involve anaesthetists in the discussion. The presence of anaesthetists at the MDT would likely reduce
269 the need for multiple case discussions and may further reduce non-implementation rates. Another
270 critical aspect is that the MDT generated treatment recommendation is not independent from the
271 individual recommendation of each physician, who will have different degrees of influence on the
272 shared decision. In order to avoid this, the study should have been conducted using individual
273 treatment recommendations from physicians who did not participate in the MDT discussion. This was
274 unfortunately not feasible in this setting. Groupthink,²⁹ where disagreement exists but is not
275 expressed, and excessive dominance by some attending physicians are two potential biases to all
276 MDTs but are difficult to quantify and to prevent. Additionally, there is a risk, in this study, of
277 excessive influence by senior vascular surgeons who consistently showed the highest agreement rate
278 in most areas. However, analyses to detect this bias is complex and goes beyond the purpose of the
279 study. From a statistical perspective, results were collected as percentages and did not follow a normal
280 distribution. Therefore, it was decided not to use medians with IQR because differences between
281 specialist groups would not be displayed, considering the reduced number of specialists for each

282 discipline. Although reporting the results with mean \pm SD is not ideal, it is largely accepted in medical
283 statistics in these cases. Finally, a selection bias exists from the exclusion of patients needing urgent
284 treatment before the next scheduled MDT. It is believed that this represents a real world situation
285 since most structured MDTs will not be able to secure the discussion of all urgent cases.

286 <H2>Conclusion

287 The impact of the MDT was clinically significant when comparing single physician treatment
288 recommendations with treatment plans generated after multidisciplinary discussion. This finding
289 supports the guideline recommendations to routinely adopt a structured multidisciplinary discussion
290 in several areas of vascular disease. The adherence to MDT treatment recommendations was in the
291 upper end when compared with available data from literature.

292 CONFLICT OF INTEREST

293 None.

294 FUNDING

295 None.

296 ACKNOWLEDGEMENTS

297 The authors would like to thank Mara Zehfus for her organisational support and Enago
298 (www.enago.com) for the language review.

299 REFERENCES

- 300 1. Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and
301 patterns of treatment on survival from breast cancer. *Lancet* 1995;**345**:1265–70.
- 302 2. Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al.
303 Multidisciplinary team working in cancer: what is the evidence? *BMJ* 2010;**340**:c951.
- 304 3. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM Impact of care at a multidisciplinary
305 congestive heart failure clinic: a randomized trial. *Can Med Assoc J* 2005;**173**:40–5.
- 306 4. Casas A, Troosters T, Gacía-Aymerich J, Roca J, Hernández C, Alonso A, et al. Integrated

- 307 care prevents hospitalisations for exacerbations in COPD patients. *Eur Respir J* 2006;**28**:123–
308 30.
- 309 5. Driver VR, Madsen J, Goodman RA. Reducing amputation rates in patients with diabetes at a
310 military medical center. *Diabetes Care* 2005;**28**:248–53.
- 311 6. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al.
312 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral
313 artery disease: a report of the American College of Cardiology/American Heart Association
314 task force on clinical practice guidelines. *Circulation* 2017;**135**:e72679.
- 315 7. Potgieter R, Hindley H, Mitchell D, McCleary J. Delivering a national quality improvement
316 programme for patients with abdominal aortic aneurysms. National Abdominal Aortic
317 Aneurysm Quality Improvement Programme Report 2012. Vascular Society of Great Britain
318 and Ireland. Available at:
319 [https://www.vascularsociety.org.uk/_userfiles/pages/files/Document%20Library/Final-](https://www.vascularsociety.org.uk/_userfiles/pages/files/Document%20Library/Final-AAAQIP-Public-Report-VSGBI-August-2012_310812.pdf)
320 [AAAQIP-Public-Report- VSGBI-August-2012_310812.pdf](https://www.vascularsociety.org.uk/_userfiles/pages/files/Document%20Library/Final-AAAQIP-Public-Report-VSGBI-August-2012_310812.pdf) [Accessed 17 March 2023].
- 321 8. Layden J, Michaels J, Bermingham S, Higgins B; Guideline Development Group. Diagnosis
322 and management of lower limb peripheral arterial disease: summary of NICE guidance. *BMJ*
323 2012;**345**:e4947.
- 324 9. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for
325 Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower
326 extremities: Management of asymptomatic disease and claudication. *J Vasc Surg* 2015;**61**:2S-
327 41S.
- 328 10. Aboyans V, Ricco JB, Bartelink MLE, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC
329 Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration
330 with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic
331 disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity
332 arteries endorsed by: the European Stroke Organization (ESO), the Task Force for the

- 333 Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of
334 Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur J Vasc*
335 *Endovasc Surg* 2018;**55**:305–68.
- 336 11. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al; GVG Writing Group for
337 the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular
338 Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global vascular
339 guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc*
340 *Surg* 2019;**58**:S1–S109.
- 341 12. Behrendt C-A, Kölbel T, Schwaneberg T, Diener H, Hohnhold R, Sebastian Debus E, et al.
342 Multidisciplinary team decision is rare and decreasing in percutaneous vascular interventions
343 despite positive impact on in-hospital outcomes. *Vasa* 2019;**48**:262–9.
- 344 13. Rimmele DL, Larena-Avellaneda A, Alegiani AC, Rosenkranz M, Schmidt NO, Regelsberger
345 J, et al. Real-world experience of treatment decision-making in carotid stenosis in a
346 neurovascular board. *Neurology* 2017;**89**:399–407.
- 347 14. Shishehbor MH, Hammad TA, Rhone TJ, Younes A, Kumins N, Abdullah A, et al. Impact of
348 interdisciplinary system-wide limb salvage Advisory Council on Lower Extremity Major
349 Amputation. *Circ Cardiovasc Interv* 2022;**15**:e011306.
- 350 15. Pandey V, Wolfe JH, Moorthy K, Munz Y, Jackson MJ, Darzi AW. Technical skills continue
351 to improve beyond surgical training. *J Vasc Surg* 2006;**43**:539–45.
- 352 16. Cohen J. A Coefficient of agreement for nominal scales. *Educ Psychol Meas* 1960;**20**:37–46.
- 353 17. Mainguene J, Basse C, Girard P, Beaucaire-Danel S, Cao K, Brian E, et al. Surgical or medical
354 strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: reproducibility of
355 decision-making at a multidisciplinary tumor board. *Lung Cancer* 2022;**163**:51–8.
- 356 18. Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RAEM, Wouters MWJM, et al.
357 Variation between multidisciplinary tumor boards in clinical staging and treatment
358 recommendations for patients with locally advanced non-small cell lung cancer. *Chest*

- 359 2020;**158**:2675–87.
- 360 19. Bujang MA, Baharum N. Guidelines of the minimum sample size requirements for Kappa
361 agreement test. *Epidemiol Biostat Public Health* 2017;**14**:e12267.
- 362 20. Look Hong NJ, Wright FC, Gagliardi AR, Paszat LF. Examining the potential relationship
363 between multidisciplinary cancer care and patient survival: an international literature review.
364 *J Surg Oncol* 2010;**102**:125–34.
- 365 21. Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P, et al. The impact of
366 multidisciplinary team meetings on patient assessment, management and outcomes in
367 oncology settings: A systematic review of the literature. *Cancer Treat Rev* 2016;**42**:56–72.
- 368 22. Schmidt HM, Roberts JM, Bodnar AM, Kunz S, Kirtland SH, Koehler RP, et al. Thoracic
369 multidisciplinary tumor board routinely impacts therapeutic plans in patients with lung and
370 esophageal cancer: a prospective cohort study. *Ann Thorac Surg* 2015;**99**:1719–24.
- 371 23. Drayton DJ, Howard S, Hammond C, Bekker HL, Russell DA, Howell SJ. Multidisciplinary
372 team decisions in management of abdominal aortic aneurysm: a service and quality evaluation.
373 *EJVES Vasc Forum* 2022;**54**:49–53.
- 374 24. Kotsougiani-Fischer D, Fischer S, Warszawski J, Gruetzner PA, Reiter G, Hirche C, et al.
375 Multidisciplinary team meetings for patients with complex extremity defects: a retrospective
376 analysis of treatment recommendations and prognostic factors for non-implementation. *BMC*
377 *Surg* 2021;**21**:168.
- 378 25. Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, et al. Cross-sectional
379 increase of adherence to multidisciplinary tumor board decisions. *BMC Cancer* 2018;**18**:936.
- 380 26. Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL. Analysis of clinical
381 decision-making in multi-disciplinary cancer teams. *Ann Oncol* 2006;**17**:457–60.
- 382 27. Lamb BW, Brown KF, Nagpal K, Vincent C, Green JSA, Sevdalis N. Quality of care
383 management decisions by multidisciplinary cancer teams: a systematic review. *Ann Surg*
384 *Oncol* 2011;**18**:2116–25.

- 385 28. Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JSA. Successful strategies in
 386 implementing a multidisciplinary team working in the care of patients with cancer: an overview
 387 and synthesis of the available literature. *J Multidiscip Healthc* 2018;**11**:49–61.
- 388 29. DiPierro K, Lee H, Pain KJ, Durning SJ, Choi JJ. Groupthink among health professional teams
 389 in patient care: a scoping review. *Med Teach* 2022;**44**:309–18.
- 390

Table 1. Rates of agreement with final vascular board decision.

Vascular district	Number of cases	Senior vascular surgeons	Junior vascular surgeons	Interventional radiologists	Angiologists	<i>p</i>
Overall	400	82 ± 30 ^{*†‡}	62 ± 45 [*]	71 ± 43 [†]	58 ± 50 [‡]	<.001
Supra-aortic vessels	54	85 ± 27 [*]	64 ± 45	44 ± 49 [*]	64 ± 50	.004
Thoracic aorta	16	78 ± 30	37 ± 50	50 ± 52	50 ± 58	.098

Aorto-iliac segment	131	81 ± 31 ^{*†}	62 ± 43 [*]	77 ± 39 [‡]	52 ± 51 ^{†‡}	<.001
Endoleaks	33	70 ± 35	52 ± 50	78 ± 39	62 ± 52	.15
Peripheral arteries	98	87 ± 24	70 ± 43	78 ± 39	62 ± 51	.008
Dialysis access	21	81 ± 29	67 ± 49	50 ± 41	50 ± 58	.12
Visceral arteries	29	79 ± 37	60 ± 42	75 ± 43	50 ± 55	.21
Central veins	12	83 ± 33	54 ± 45	71 ± 39	100 ± 0	.22
Malformations	6	92 ± 38	20 ± 45	83 ± 41	100 ± 0	.046


391 Continuous variables are expressed as mean percentage ± standard deviation for agreement with
 392 board decisions.

393 *†‡Indicate a statistically significant difference between groups ($p < .005$).

394 **Figure 1.** Histogram depicting the agreement rate of the different specialists with the final

395 multidisciplinary team decision considering all vascular districts discussed.

Journal Pre-proof



Short title: Impact of Multidisciplinary Team Meetings

Figure 1: follow pages E1 and E2

Supplementary material

Supplementary file, MDM digital platform with translation

Supplementary file, MDM protocol

Supplementary file, Patient MDM form, with translation

Supplementary file, Regolamento_MDM Vascolare

Supplementary file, Regulation MDM translated